Abstract
This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.
Keywords:
Antivirals; clinical management; immunocompromised; influenza; respiratory; treatment.
© 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Communicable Diseases, Emerging
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / epidemiology
-
Humans
-
Immunocompromised Host
-
Influenza Vaccines
-
Influenza, Human* / drug therapy
-
Influenza, Human* / epidemiology
-
Influenza, Human* / prevention & control
-
Influenza, Human* / virology
-
Middle East Respiratory Syndrome Coronavirus
-
Pandemics
-
Respiratory Syncytial Virus Infections / drug therapy
-
Respiratory Syncytial Virus Infections / epidemiology
-
Respiratory Tract Infections* / drug therapy
-
Respiratory Tract Infections* / epidemiology
-
Respiratory Tract Infections* / prevention & control
-
Respiratory Tract Infections* / virology
-
Virus Diseases* / drug therapy
-
Virus Diseases* / epidemiology
-
Virus Diseases* / virology
Substances
-
Antiviral Agents
-
Influenza Vaccines